Monetizing Technology Leadership Nine-month results Scientific Excellence Operational Excellence Evotec SE, 9M 2025 results call, 05 November 2025 Agenda PAGE 3 1. 9M/Q3 review 2. Monetizing Technology Leadership 3. On track to reach 2028 outlook 4. Questions & Answers Disclaimer This presentation (including any information which has been or may be supplied in writing or orally in connection herewith or in connection with any further inquiries) is being delivered on behalf of Evotec SE (the "Company", "we," ...

November 5, 2025 Third-Quarter 2025 Earnings Update Safe Harbor Certain statements in this material, other than statements of historical or current fact, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Exchange Act. These statements include, but are not limited to, LivaNova's plans, objectives, strategies, financial performance and outlook, trends, the amount and timing of future cash distr ...

THIRD QUARTER 2025 Earnings Conference Call Presentation NOVEMBER 5, 2025 FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on our current expectations, beliefs, and assumptions, and are not guarantees of future performance. Forward-looking stat ...

Avient Corporation AVNT Q3 2025 results 2025 full-year financial guidance NOVEMBER 5, 2025 Disclaimer Forward-looking statements Certain statements contained in or incorporated by reference into this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events and are not guarantees of future performance. They are based on management's expectations that invol ...

2Q25 (L)earnings August 2025 Important Information This presentation of Recursion Pharmaceuticals, Inc. ("Recursion," "we," "us," or "our") and any accompanying discussion contain statements that are not historical facts may be considered forward-looking statements under federal securities laws and may be identified by words such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "potential," "predicts," "projects," "seeks," "should," "will," or words of similar meaning and include, b ...

业绩总结 - 2025年前九个月销售额为229,920百万丹麦克朗，同比增长12%[68] - 2025年前九个月的毛利润为186,280百万丹麦克朗，同比增长8%[68] - Novo Nordisk的净利润为75,543百万丹麦克朗，同比增长4%[68] - 销售增长率为15%（按固定汇率计算），营业利润增长率为10%（按固定汇率计算）[11] - 自由现金流为639亿丹麦克朗，532亿丹麦克朗已返还给股东[11] 用户数据 - 2024年Novo Nordisk的糖尿病产品治疗人数为4300万，约占589百万糖尿病患者的7.3%[121] - 全球约有5.5亿人患有糖尿病，90%在美国以外[185] - 全球约有9亿人患有肥胖症，90%在美国以外[185] 市场份额与增长 - Novo Nordisk在糖尿病市场的份额为31.6%，较去年下降2.3个百分点[11][118] - GLP-1类药物在国际业务中的市场份额为68%[30] - Novo Nordisk在肥胖市场的份额为53%，市场增长率为122%[194] - Novo Nordisk在GLP-1市场的市场份额为59%，并预计在2025年将继续增长[91] 未来展望 - 预计2025年销售增长（按固定汇率计算）为8%至11%[69] - 预计2025年运营利润增长（按固定汇率计算）为4%至7%[69] - 预计2025年自由现金流为200亿至300亿丹麦克朗[69] - 预计抗肥胖药物市场将受到多个细分市场和患者偏好的推动[43] 新产品与技术研发 - Efruxifermin在F4阶段的患者中显示出统计学显著的纤维化回归[51] - Cagrilintide 2.4 mg在REDEFINE 1试验中显示出83%的患者在试验结束时使用最高剂量[59] - Novo Nordisk的研发管道涵盖糖尿病、心血管疾病、肥胖等多个领域，支持未来的显著增长机会[109] - Novo Nordisk计划在2025年前实现每年平均3项1期临床试验的启动目标[102] 并购与合作 - Novo Nordisk与BMI签署协议，交易金额为72亿美元，涉及50%的非投票优先股[47] 负面信息 - 糖尿病市场份额为31.6%，较去年下降2.3个百分点[11] 其他策略 - 预计通过组织转型实现每年约80亿丹麦克朗的节省，以再投资于未来增长[17] - 公司计划在糖尿病和肥胖领域进行更多投资，以应对日益激烈的市场竞争[21]

KPN Strategy Update | November 5, 2025 Connect Activate Grow Agenda 2 | KPN Strategy Update | November 2025 1. Progress so far 2. Infrastructure Value: Driving connected asset value 3. Transformation Value: Activating the change engine to deliver strategic value 4. Customer Value: Growing by differentiated offerings to customers 5. Financial Value: Financial framework and outlook 6. Q&A Strengthening Our Position via M&A, strategic partnerships and portfolio expansion 3 | KPN Strategy Update Our Progress | ...

FY2026 Second Quarter Financial Results November 5, 2025 Toyota Motor Corporation CENTURY Cautionary Statement with Respect to Forward-Looking Statements and Caution Concerning Insider Trading This presentation contains forward-looking statements that reflect the plans and expectations of Toyota Motor Corporation and its consolidated subsidiaries ("Toyota"). These forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that may ...

Zepp Health Earnings Presentation Third Quarter 2025 Investor Relations 4 November 2025 Table of Contents Adjusted Operating Expenses 2 Empowering Health, Inspiring Joy 3Q25 Financial and Operating Results 01 05 02 Revenue 03 3Q25 Gross Margin 04 3Q25 Revenue and Gross Margin Trend Net Income/ Earnings Performance 06 Liquidity Position 07 08 Business Outlook 3Q25 Financial and Operating Results $75.8 Million Revenue • Meeting upper end of guidance range Units Shipped 0.8 Million 3Q24 0.7 Million 0.0 Million ...

业绩总结 - 2025年第三季度，HKEX的收入和其他收入达到218亿港元，同比增长37%[8] - 股东应占利润为49亿港元，同比增长56%[10] - 核心业务收入为75亿港元，同比增长54%[15] - EBITDA为62亿港元，同比增长59%[15] - 整体收入和利润均创下新季度高点，主要受现金市场交易量创纪录的推动[57] 用户数据 - 2025年第三季度，平均每日交易量（ADT）同比增长126%，达到1188亿港元[21] - 北向股票通的ADT同比增长67%[12] - 南向股票通的ADT同比增长229%[12] - 股票通的收入创下32亿港元的历史新高，同比增长81%[37] - 股票通南向交易在2025年第三季度的平均日成交额达到港币1525亿元，同比增长285%[78] 未来展望 - 2025年第三季度，首次公开募股（IPO）数量达到69个，筹集资金1883亿港元，是2024年同期的三倍多[37] - 股票通的南向交易占香港市场的比例在持续增长[78] 新产品和新技术研发 - 2025年第三季度，保证金资金的净投资收入同比增长16%，主要得益于香港的平均基金规模提高[30] - 保证金资金总额为1445亿港元，较2024年第三季度的984亿港元增长47%[31] 负面信息 - 截至2025年第三季度，外部投资组合收益同比下降39%，主要由于基金规模减少[30] - 净投资收入为10.18亿港元，较2024年第三季度的12.07亿港元下降了16%[60] - 外部投资组合收益同比下降78%，主要由于基金规模减少[65] 其他新策略和有价值的信息 - 2025年第三季度，运营费用同比增长7%，反映出对人才、基础设施和运营卓越的审慎投资[32] - 股票通的收入在2025年第三季度占集团总收入和其他收入的15%，相比2024年同期的11%有所增长[78]